Health Care & Life Sciences » Biotechnology | Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc. | Mutual Funds

Mutual Funds that own Neurocrine Biosciences Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
BB Biotech AG
3,402,753
3.76%
-60,000
10.07%
03/31/2018
Fidelity Contrafund
2,963,521
3.28%
-319
0.27%
07/31/2018
T Rowe Price Health Sciences Fund
2,350,166
2.6%
-35,742
2.27%
06/30/2018
Vanguard Small Cap Index Fund
2,261,953
2.5%
29,160
0.28%
07/31/2018
Vanguard Total Stock Market Index Fund
2,255,500
2.49%
2,346
0.04%
07/31/2018
Fidelity Select Biotechnology Portfolio
1,927,151
2.13%
-44,700
2.58%
07/31/2018
Janus Enterprise Fund
1,825,633
2.02%
0
1.17%
06/30/2018
T Rowe Price New Horizons Fund
1,788,746
1.98%
-157,063
0.9%
06/30/2018
Vanguard Small Cap Growth Index Fund
1,291,418
1.43%
18,334
0.62%
07/31/2018
Vanguard Extended Market Index Fund
1,191,667
1.32%
0
0.2%
07/31/2018

About Neurocrine Biosciences

View Profile
Address
12780 El Camino Real
San Diego California 92130
United States
Employees -
Website http://www.neurocrine.com
Updated 07/08/2019
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.